Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5043216 | 0.71 | NPC1 (0.44) | ALDH1A1 | |
| SCHEMBL140621 | 0.68 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL30112896 | 0.67 | CLK1 (0.43) | ALDH1A1 | |
| 2-Aminopurine SCHEMBL5631 | 0.67 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL29802574 | 0.67 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL1644969 | 0.67 | ALDH1A1 (0.38) | ALDH1A1 | |
| 2-Aminopurine SCHEMBL29901502 | 0.67 | ALDH1A1 (0.48) | ALDH1A1 | |
| 2-Aminopurine SCHEMBL28283405 | 0.65 | ALDH1A1 (0.47) | ALDH1A1 | |
| SCHEMBL1839886 | 0.65 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL5942175 | 0.64 | BCL6 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143643-A1 | LOW DK COPPER CLAD LAMINATE COMPOSITIONS | DESIGNER MOLECULES INC (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230095931-A1 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | DESIGNER MOLECULES INC (US) | 2023-03-30 | — | — | US | disclosed |
| EP-4097756-A2 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | Designer Molecules, Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| US-20220213267-A1 | EXTREME HIGH TEMPERATURE STABLE ADHESIVES AND COATINGS | DESIGNER MOLECULES, INC | 2022-07-07 | — | — | US | disclosed |
| US-20220204766-A1 | HIGH MOLECULAR WEIGHT FLEXIBLE CURABLE POLYIMIDES | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | disclosed |
| US-20220204696-A1 | PHENOLIC FUNCTIONALIZED POLYIMIDES AND COMPOSITIONS THEREOF | DESIGNER MOLECULES, INC | 2022-06-30 | — | — | US | disclosed |
| US-20210301133-A1 | CURABLE POLYIMIDES | DESIGNER MOLECULES INC (US) | 2021-09-30 | — | — | US | disclosed |
| WO-2021154898-A2 | UV-CURABLE RESIN COMPOSITIONS SUITABLE FOR REDISTRIBUTION LAYERS | DESIGNER MOLECULES, INC (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021113415-A1 | LOW DK COPPER CLAD LAMINATE COMPOSITIONS | DESIGNER MOLECULES, INC (US) | 2021-06-10 | — | — | WO | disclosed |
| CN-108291122-B | Anionically curable compositions | 设计分子有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | AUSPEX PHARMACEUTICALS, INC. | 2007-04-12 | — | — | US | disclosed |
| US-7138399-B2 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2006-11-21 | — | — | US | disclosed |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | HONG BORCHERNG | 2006-08-03 | — | — | US | disclosed |
| WO-2006041921-A2 | PREPARATION AND USES OF RHODANINE DERIVATIVES | AUSPEX PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1594835-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | Auspex Pharmaceuticals, Inc. (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | ALTANA PHARMA AG (DE) | 2005-08-04 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
| EP-1490366-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA Pharma AG (DE) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004064745-A2 | METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2003080607-A1 | NOVEL ALKOXYPYRIDINE-DERIVATIVES | ALTANA PHARMA AG (DE) | 2003-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082929-A1 | Inhibitors of the gastric H+, K+-atpase with enhanced therapeutic properties | ATP4A, ATP6V1G1, ATP6V1E1 | ALDH1A1 2327/4885 |
| US-20050171125-A1 | 2-[2-(4-alkoxypyridin-2-yl)alkyl])-3H-imidazo[4,5-b]pyridine derivatives and 8-[2-(4-alkoxypyridin-2-yl)alkyl])-9H-purine derivatives; used to treat an acute inflammatory disease in which the activity of inducible NO-synthase is involved | NOS2, PNP, PTGIS | ALDH1A1 650/4885 |
| US-20060173199-A1 | Method of preparation of heterocyclic molecules with pharmaceutical, pharmaceutical excipient, cosmeceutical, agrochemical and industrial uses | LSS, DHPS, CYP51A1 | ALDH1A1 1435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.